Being included in the "KPMG China's First 50 Biotechnology Innovation Enterprises" is the recognition of Hopstem's strength by the selection agencies and industry experts, and it is also a highly recognition of Hopstem's innovative technology. Hopstem is an innovative research and development enterprise dedicated to providing stable, safe, effective, and affordable iPSC cell therapy products for patients around the world.

Hopstem has always been adhering to the mission of benefiting patients with innovative iPSC cell therapy, and the values of responsibility, value, and win-win. In the future, Hopstem will further accelerate its pace to develop more clinical products of great value for patients.